ECSP13012392A - Cristal de compuesto de amida - Google Patents
Cristal de compuesto de amidaInfo
- Publication number
- ECSP13012392A ECSP13012392A ECSP13012392A ECSP13012392A EC SP13012392 A ECSP13012392 A EC SP13012392A EC SP13012392 A ECSP13012392 A EC SP13012392A EC SP13012392 A ECSP13012392 A EC SP13012392A
- Authority
- EC
- Ecuador
- Prior art keywords
- crystal
- amida
- ylcarbonyl
- methoxybutyl
- morpholin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Se describe un cristal de clorhidrato de 1-(4-metoxibutil)-N-(2-metilpropil)-N-[(3S,5R)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1H-bencimidazol-2-carboxamida que tiene excelente actividad inhibitoria de renina que es útil como un conservador u otro agente terapéutico para tipos de disfunción de órganos y similares, que se derivan de alta presión sanguínea e hipertensión. El cristal de clorhidrato de 1-(4-metoxibutil)-N-(2-metilpropil)-N-[(3S,5R)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1H-bencimidazol-2-carboxamida tiene un patrón de difracción de rayos-X de polvo, en donde el espaciamiento de celosía (d) del patrón de difracción de rayos-X de polvo, tiene picos característicos que aparecen en los alrededores de 26.43 ± 0.2, 7.62 ± 0.2 y 4.32 ± 0.2 angstroms.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010137194 | 2010-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP13012392A true ECSP13012392A (es) | 2013-03-28 |
Family
ID=45348277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP13012392 ECSP13012392A (es) | 2010-06-16 | 2013-01-16 | Cristal de compuesto de amida |
Country Status (27)
Country | Link |
---|---|
US (1) | US9018374B2 (es) |
EP (1) | EP2583967B1 (es) |
JP (1) | JP5782438B2 (es) |
KR (1) | KR20130119903A (es) |
CN (1) | CN103068816B (es) |
AU (1) | AU2011266099B2 (es) |
BR (1) | BR112012032055B8 (es) |
CA (1) | CA2802483C (es) |
CL (1) | CL2012003526A1 (es) |
CO (1) | CO6670573A2 (es) |
DO (1) | DOP2012000313A (es) |
EA (1) | EA022094B1 (es) |
EC (1) | ECSP13012392A (es) |
ES (1) | ES2524896T3 (es) |
GE (1) | GEP20146195B (es) |
HK (1) | HK1179605A1 (es) |
IL (1) | IL223562A (es) |
MA (1) | MA34378B1 (es) |
MX (1) | MX2012014828A (es) |
MY (1) | MY163927A (es) |
PE (1) | PE20130283A1 (es) |
SG (1) | SG186223A1 (es) |
TN (1) | TN2012000589A1 (es) |
TW (1) | TWI511967B (es) |
UA (1) | UA108888C2 (es) |
WO (1) | WO2011158880A1 (es) |
ZA (1) | ZA201300065B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9382192B2 (en) * | 2012-02-14 | 2016-07-05 | Dow Global Technologies Llc | Nonionic surfactant compositions |
JP6077555B2 (ja) * | 2012-02-15 | 2017-02-08 | 武田薬品工業株式会社 | 錠剤 |
CN103831159B (zh) * | 2014-01-20 | 2016-04-13 | 华润赛科药业有限责任公司 | 一种阿齐沙坦微粉化方法 |
US9878981B2 (en) * | 2014-04-10 | 2018-01-30 | Takeda Pharmaceutical Company Limited | Method for producing heterocyclic compound |
GB2542876B (en) * | 2015-04-20 | 2019-10-23 | Johnson Matthey Plc | Structure Directing Agent |
CN107595842A (zh) * | 2017-10-25 | 2018-01-19 | 桂林浩新科技服务有限公司 | 一种药物复方制剂及在制备治疗高血压合并冠心病的药物中的用途 |
CN107595853A (zh) * | 2017-10-25 | 2018-01-19 | 桂林浩新科技服务有限公司 | 一种用于治疗高血压合并冠心病的药物组合物及其用途 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
AU2001269531A1 (en) | 2000-07-17 | 2002-01-30 | Takeda Chemical Industries Ltd. | Sulfone derivatives, process for their production and use thereof |
US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
MXPA05004505A (es) | 2002-11-01 | 2005-07-26 | Takeda Pharmaceutical | Agente para prevenir o tratar la neuropatia. |
EP1559422B1 (en) | 2002-11-08 | 2014-04-30 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
CA2507026A1 (en) | 2002-11-22 | 2004-06-10 | Takeda Pharmaceutical Company Limited | Imidazole derivatives, their production and use |
JP3618341B2 (ja) * | 2003-04-15 | 2005-02-09 | 山之内製薬株式会社 | 臭化物及びその結晶 |
KR101015034B1 (ko) | 2003-04-15 | 2011-02-16 | 아스텔라스세이야쿠 가부시키가이샤 | 브롬화물 및 이의 결정 |
EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONNECTION WITH CONDENSED RING |
EP1641779A1 (en) | 2003-06-18 | 2006-04-05 | AstraZeneca AB | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
RU2006126978A (ru) | 2003-12-25 | 2008-01-27 | Такеда Фармасьютикал Компани Лимитед (Jp) | Производные 3-(4-бензилоксифенил)пропановой кислоты |
JP4855777B2 (ja) | 2003-12-26 | 2012-01-18 | 武田薬品工業株式会社 | フェニルプロパン酸誘導体 |
JP4875978B2 (ja) | 2004-03-15 | 2012-02-15 | 武田薬品工業株式会社 | アミノフェニルプロパン酸誘導体 |
EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
EP1873144B1 (en) | 2005-04-20 | 2014-07-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
ES2434072T3 (es) | 2005-06-09 | 2013-12-13 | Norgine Bv | Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona |
GB0514203D0 (en) | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
EP1911738A4 (en) | 2005-07-29 | 2009-12-16 | Takeda Pharmaceutical | PHENOXYALKANSÄUREVERBINDUNG |
WO2007013689A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | シクロプロパンカルボン酸化合物 |
AU2006277231A1 (en) | 2005-08-10 | 2007-02-15 | Takeda Pharmaceutical Company Limited | Therapeutic agent for diabetes |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
US8492405B2 (en) | 2006-10-18 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity |
NZ576570A (en) | 2006-10-19 | 2010-11-26 | Takeda Pharmaceutical | 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds |
JPWO2008093639A1 (ja) | 2007-01-29 | 2010-05-20 | 武田薬品工業株式会社 | ピラゾール化合物 |
EA200970746A1 (ru) | 2007-02-09 | 2010-02-26 | Такеда Фармасьютикал Компани Лимитед | Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма |
WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素5員複素環化合物 |
EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
JP2010229034A (ja) | 2007-07-26 | 2010-10-14 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピロール誘導体 |
TWI378096B (en) | 2008-06-19 | 2012-12-01 | Takeda Pharmaceutical | Heterocyclic compound and use thereof |
JP4901849B2 (ja) | 2008-12-15 | 2012-03-21 | バブコック日立株式会社 | 空気清浄機、及び分析室、並びに空気の浄化方法 |
US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
-
2011
- 2011-06-15 MY MYPI2012005311A patent/MY163927A/en unknown
- 2011-06-15 PE PE2012002427A patent/PE20130283A1/es active IP Right Grant
- 2011-06-15 US US13/704,039 patent/US9018374B2/en not_active Expired - Fee Related
- 2011-06-15 BR BR112012032055A patent/BR112012032055B8/pt not_active IP Right Cessation
- 2011-06-15 ES ES11795784.5T patent/ES2524896T3/es active Active
- 2011-06-15 MX MX2012014828A patent/MX2012014828A/es active IP Right Grant
- 2011-06-15 CA CA2802483A patent/CA2802483C/en not_active Expired - Fee Related
- 2011-06-15 WO PCT/JP2011/063735 patent/WO2011158880A1/ja active Application Filing
- 2011-06-15 CN CN201180039608.XA patent/CN103068816B/zh active Active
- 2011-06-15 SG SG2012090122A patent/SG186223A1/en unknown
- 2011-06-15 JP JP2012520480A patent/JP5782438B2/ja not_active Expired - Fee Related
- 2011-06-15 TW TW100120982A patent/TWI511967B/zh not_active IP Right Cessation
- 2011-06-15 GE GEAP201112963A patent/GEP20146195B/en unknown
- 2011-06-15 UA UAA201300523A patent/UA108888C2/ru unknown
- 2011-06-15 AU AU2011266099A patent/AU2011266099B2/en not_active Ceased
- 2011-06-15 EA EA201291453A patent/EA022094B1/ru not_active IP Right Cessation
- 2011-06-15 KR KR1020137000759A patent/KR20130119903A/ko active Search and Examination
- 2011-06-15 EP EP11795784.5A patent/EP2583967B1/en active Active
- 2011-06-16 MA MA35560A patent/MA34378B1/fr unknown
-
2012
- 2012-12-11 IL IL223562A patent/IL223562A/en active IP Right Grant
- 2012-12-13 TN TNP2012000589A patent/TN2012000589A1/en unknown
- 2012-12-13 CL CL2012003526A patent/CL2012003526A1/es unknown
- 2012-12-14 DO DO2012000313A patent/DOP2012000313A/es unknown
-
2013
- 2013-01-03 ZA ZA2013/00065A patent/ZA201300065B/en unknown
- 2013-01-15 CO CO13006575A patent/CO6670573A2/es unknown
- 2013-01-16 EC ECSP13012392 patent/ECSP13012392A/es unknown
- 2013-06-04 HK HK13106577.3A patent/HK1179605A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP13012392A (es) | Cristal de compuesto de amida | |
CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
NZ715331A (en) | Substituted (e)-n’-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors | |
CL2008002998A1 (es) | Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion. | |
PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
CR20130281A (es) | Compuesto bicíclico | |
NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
CL2015002680A1 (es) | Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos | |
UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
UY35738A (es) | Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso | |
CR10748A (es) | Compuesto de indol | |
AR069886A1 (es) | Formas cristalinas de n-(terc-butoxicarbonil)-3-metil-l-valil-(4r)-4-((7-cloro-4-metoxi-1-isoquinolinil)oxi)-n-((1r,2s)-1-((ciclopropilsulfonil)carbamoil)-2-vinilciclopropil)-l-prolinamida | |
NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
PE20140040A1 (es) | Composicion farmaceutica que comprende un inhibidor de la actividad de mek | |
CY1110669T1 (el) | Χρησιμοποιηση βενζο-συγχωνευμενων ετεροκυκλικων παραγωγων σουλφαμιδιου για τη θεραπευτικη αγωγη της καταθλιψης | |
BRPI0815591B8 (pt) | composto, composição farmacêutica, e, uso de um composto. | |
AR092727A1 (es) | Compuestos heterociclicos que contienen nitrogeno para combatir fitoenfermedades | |
UY31554A1 (es) | Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus | |
SV2010003526A (es) | Benzotiazoles como moduladores del receptor de grelina | |
CO2019002517A2 (es) | Inhibidores de dopamina–β–hidroxilasa | |
CO2017005990A2 (es) | Combinaciones de compuestos activos que comprenden (a) una carboxamida de indanilo difluorometil-nicotínico de fórmula (i) y otro compuesto activo como fungicida (b) | |
PE20190150A1 (es) | 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT | |
CL2011002045A1 (es) | Compuesto derivado de n-[(3e)-5-(cicloalquilamino)-5-oxo-1-fenilpent-3-en-2-il]benzamida, utiles en el tratamiento del prurito de causa desconocido o asociado a una enfermedad dermatologica tal como dermatitis atopica, psoriasis, urticaria, entre otras; combinacion farmaceutica. |